This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

Non-Medical Prescribing (NMP) Service Resources

Pfizer Oncology recognise the increasing importance of Non Medical Prescribing clinicians (NMPs) in supporting the patient pathway for many oral systemic anti-cancer therapies (SACTs), particularly where patients are stable. NMP clinicians play a vital role in supporting the delivery of cancer services in the NHS.

Pfizer Oncology have commissioned the services of subject matter expert Professor Nicola Stoner, Consultant Pharmacist at Oxford University Hospitals NHS Foundation Trust to produce some NMP materials. The purpose of these materials is to support the development and future proofing of NMP services within Oncology. Their aim is to enhance service experience and improve outcomes for patients. 

These resources include:
​​​​​​​- a Business Case Toolkit, in the form of a pdf presentation
- a customisable template: Business Case for NMP Clinics 
- a Checklist Template for CDK4/6 inhibitor Toxicity Review

Business Case Toolkit

NMP Business Case Toolkit

A  presentation to support Healthcare Professionals in setting up NMP services within their Trusts

Download

Business case template for NMP clinics

NMP Business Case Template

A business case template for NMP clinics, in a word document that is easy to customise for your trust.

Download

Checklist Template for CDK4/6 inhibitor Toxicity Review

NMP Checklist Template for CDK4/6 inhibitor Toxicity Review

A downloadable checklist to facilitate a side-effects review.

Download

PP-IBR-GBR-3946. April 2022

Resources

Resources to assist you and your patients
  • Adapting Breast Cancer Care during COVID-19 Pandemic
  • mBC Models of Care
  • Ibrance® Dispense and Delivery Service
    ​​​​​​​
    Materials
    ​​​​​​​
    Videos

Header

This text is for block level content. P tags can go in here too

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?